Literature DB >> 18501069

Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.

Lieke Simkens1, Jolien Tol, Miriam Koopman, Linda Mol, Ninja Antonini, Hans van Krieken, Cornelis Punt.   

Abstract

The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies. The Dutch Colorectal Cancer Group (DCCG) is a national multidisciplinary clinical research group in The Netherlands. The 3 CAIRO studies of the DCCG address clinically relevant questions in patients with advanced colorectal cancer: the benefit of combination versus sequential therapy, targeting vascular endothelial growth factor and epidermal growth factor receptor, and the role of maintenance therapy. This article presents the outline of these studies and summarizes the current results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501069     DOI: 10.3816/CCC.2008.n.014

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  2 in total

1.  Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer.

Authors:  Mohammad H Rashid; Mersiha Hadziahmetovic; Uzair B Chaudhary
Journal:  Gastrointest Cancer Res       Date:  2012-09

Review 2.  Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.

Authors:  Josué Barahona-Garrido; Jorge Hernández-Calleros; Ignacio García-Juárez; Jesús K Yamamoto-Furusho
Journal:  Saudi J Gastroenterol       Date:  2009 Jul-Sep       Impact factor: 2.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.